Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
← catalyst calendarNCT06577090 · readout in 92 d
Sponsored by Skye Bioscience, Inc. (industry) · SKYE — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
136actual
Sites
16
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-22 | actual | When the study began enrolling |
| Primary completion | 2026-11-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity
Interventions
- Biological: Nimacimab injection
- Biological: Nimacimab placebo injection
- Combination product: semaglutide injection
- Biological: Nimacimab 300 mg injection
Primary outcomes
what the primary-completion date above is the date OFPercent change in body weight (main study)
measured From Baseline to Week 26
Nature, frequency and severity of AEs (study extension)
measured Baseline through Week 38 of study extension (approximately 10 months of participation)
Permalink · SKYE's whole pipeline · Catalyst calendar · Every registered study · What changed